secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-06-05T20:29:35+00:00
Accession:  0001645113-26-000050
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure shareholders elect 11 directors, approve incentive plan by slim margin at 2026 AGM
--------------------------------------------------------------------------------

- All 11 director nominees elected with 79.5M to 82.5M for votes; term expires 2027.
- Ratified Kost Forer Gabbay & Kasierer as independent auditor for FY2026: 91.4M for, 2.3M against.
- Advisory vote to approve executive compensation passed: 75.4M for vs 7.4M against.
- Amended & Restated 2024 Omnibus Incentive Plan approved by narrow margin: 41.68M for, 41.16M against (plus 10.87M broker non-votes).
- 93.8M shares represented (81% of entitled) at the June 3, 2026 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/0001645113-26-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/nvcr-20260603.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer